A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

First published 17/02/2017

Last updated 14/03/2024

EU PAS number:

EUPAS17875

Study

Finalised

Documents

Study protocol

Initial protocol

GS-US-334-1113-appendix-16.1.1-protocol_f-redact

English (876.81 KB - PDF)View document

Updated protocol

GS-US-334-1113-appendix-16.1.1-protocol Amendment 3_f-redact

First published: 22/02/2024

English (829.86 KB - PDF)View document

Study results

GS-US-334-1113-CSR-synopsis_f-redact

English (724.29 KB - PDF)View document

Study report

Other information

Secondary tabs